RxDoctor Payments Data

Terry Hummer, MD

Family Medicine · Philippi, WVNPI 1568560035

Payments from drug & device makers

$1,885in general payments, 2019–2025

Across 90 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$511
  • AstraZeneca$335
  • Novo Nordisk$248
  • Sanofi-aventis U.S. LLC$228
  • Bayer$97
  • Novartis$90
  • plus $375 from 15 others

What the payments were for

  • Food & beverage$1,885100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,885 in reported general payments places this provider in the 75th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$8,154
Medicare patients
44
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$79,876
EliquisApixaban16$25,091
TrulicityDulaglutide11$24,026
XareltoRivaroxaban12$19,996
MounjaroTirzepatide11$19,602
Breo ElliptaFluticasone/Vilanterol23$11,506
Levothyroxine Sodium93$2,574
Valsartan49$1,693
Duloxetine Hcl44$1,245
Clonidine16$1,089
Metoprolol Succinate65$775
Atorvastatin Calcium92$720
Ezetimibe36$670
Simvastatin63$625
Omeprazole48$565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$248$79,87638 claims
Lilly USA, LLCTrulicity, Mounjaro$12$43,62822 claims
Johnson & JohnsonXarelto$28$19,99612 claims
GSKBreo Ellipta$20$11,50623 claims
AbbVieSynthroid$511$38128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Philippi

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →